{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-019754","form_type":"8-K","ticker":"COGT","cik":"0001622229","company_name":"Cogent Biosciences, Inc.","filed_at":"2024-02-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.843710+00:00","generated_at":"2026-06-05T15:14:20.672105+00:00","sec_items":["2.02","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Cogent Biosciences reports Q4/FY2023 net loss; $487M pro-forma cash; bezuclastinib trials on track","bullets":["Q4 2023 net loss $54.4M; FY2023 net loss $192.4M (up from $140.2M YoY); R&D expenses $173.8M for 2023.","Cash $273.2M at Dec 31, 2023; $225M PIPE closed Feb 2024 at $7.50/share (37% premium); pro-forma $487M funds into 2027.","Three registration-directed bezuclastinib trials enrolling: SUMMIT (NonAdvSM), APEX (AdvSM), PEAK (GIST); topline results expected in 2025.","SUMMIT Part 1b data: 51% mean TSS improvement, 70% of patients with ≥50% improvement; 100 mg RP2D selected.","PEAK lead-in: 33% confirmed ORR in 2nd-line GIST; bezuclastinib+sunitinib combination well-tolerated."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-019754","json":"https://secwatch.observer/filing/0000950170-24-019754.json","markdown":"https://secwatch.observer/filing/0000950170-24-019754.md","text":"https://secwatch.observer/filing/0000950170-24-019754.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1622229/000095017024019754/0000950170-24-019754-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1622229/000095017024019754/cogt-20240226.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T15:14:20.672105+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"8ae6d28addf9579c1a8a17603854a2f4d7d66d43","claim":"Cogent Biosciences, Inc. reported financial results for the quarter and year ended December 31, 2023.","evidence_excerpt":"On February 26, 2024, Cogent Biosciences, Inc., a Delaware corporation (the “Company”), issued a press release announcing its financial results for the quarter and year ended December 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1622229/000095017024019754/0000950170-24-019754-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter and year ended December 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}